EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
作者： Martin Früh , Miklos Pless
DOI: 10.3978/J.ISSN.2218-6751.2012.03.01
关键词: Oncology 、 Medicine 、 Non small cell 、 Epidermal growth factor receptor 、 Crizotinib 、 Kinase 、 Cetuximab 、 Clinical Practice 、 Lung cancer 、 Immunohistochemistry 、 Internal medicine 、 Bioinformatics
摘要: The discovery of activating epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase gene rearrangement led to significantly improved outcomes with EGFR-tyrosine inhibitors (TKIs) crizotinib, respectively. These results have revolutionized treatment algorithms in non-small cell lung cancer (NSCLC), which are now, - at least part-, biomarker-guided. advantage this approach is obvious, allowing active treatments be offered a selected group patients who more likely benefit.
amegroups.com参考文章(7)
T. Lynch, P. Bhagavatheeswaran, P. Mukhopadhyay, S. Khambata-Ford, C.T. Harbison, 9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane European Journal of Cancer. ,vol. 47, ,(2011) , 10.1016/S0959-8049(11)72313-9
Jan B. Vermorken, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, Dmytro Zabolotnyy, Heinz-Roland Kienzer, Didier Cupissol, Frederic Peyrade, Marco Benasso, Ihor Vynnychenko, Dominique De Raucourt, Carsten Bokemeyer, Armin Schueler, Nadia Amellal, Ricardo Hitt, Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer The New England Journal of Medicine. ,vol. 359, pp. 1116- 1127 ,(2008) , 10.1056/NEJMOA0802656
Shirin Khambata-Ford, Christopher T. Harbison, Lowell L. Hart, Melissa Awad, Li-An Xu, Christine E. Horak, Shaker Dakhil, Robert C. Hermann, Thomas J. Lynch, Martin R. Weber, Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 918- 927 ,(2010) , 10.1200/JCO.2009.25.2890
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Robert Pirker, Jose R Pereira, Joachim Von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo De Marinis, Wilfried EE Eberhardt, Luis Paz-Ares, Stephan Störkel, Karl-Maria Schumacher, Anja Von Heydebreck, Ilhan Celik, Kenneth J O'Byrne, None, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncology. ,vol. 13, pp. 33- 42 ,(2012) , 10.1016/S1470-2045(11)70318-7
Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth O'Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, Ulrich Gatzemeier, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet. ,vol. 373, pp. 1525- 1531 ,(2009) , 10.1016/S0140-6736(09)60569-9
Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer, Michael N. Needle, Justin Kopit, Robert J. Mayer, Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor Journal of Clinical Oncology. ,vol. 22, pp. 1201- 1208 ,(2004) , 10.1200/JCO.2004.10.182